Phase 3 N=498 Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Lymphoblastic Leukemia, Acute
Primary: Overall Event-free Survival (EFS) — 87.3 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=120 Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: 3-Year Event-Free Survival (EFS) — 68 Participants
Phase 2 N=106 Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Leukemia, Pediatric
Primary: 3-year Event-free Survival (EFS) Rate — 66.0 Percentage of Participants — p=0.032
Phase 2 N=42 Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Phase 3 N=5,377 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia · Childhood B Acute Lymphoblastic Leukemia
Primary: Event-free Survival (EFS) for SR-Average ALL Patients — 83.82; 88.89; 88.34; 90.51 percent probability
Phase 1 N=12 Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Leukemia, Lymphocytic · Lymphoblastic Lymphoma · T-cell Lymphoma
Primary: Frequency of Dose Limiting Toxicities of Palbociclib — 1; 0 Participants
Phase 3 N=4,973 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
B Acute Lymphoblastic Leukemia · B Acute Lymphoblastic Leukemia, BCR-ABL1-Like · Central Nervous System Leukemia
Primary: DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified…
Phase 1 N=24 AC220 for Children With Relapsed/Refractory ALL or AML
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
Phase 2 N=40 Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia · Lymphoma, Lymphoblastic
Primary: Response Rate — 0.846; 0.786; 0.154; 0.214 proportion of participants
Phase 3 N=1,895 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
T Acute Lymphoblastic Leukemia · T Lymphoblastic Lymphoma
Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability
Phase 2 N=23 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Phase 2 N=318 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Leukemia
Primary: Complete Response Rate — 89 percentage of patients
Phase 2 N=38 NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia
Leukemia, Lymphocytic, Acute
Primary: Toxicity of Treatment in Terms of Number of Participants With Serious Adverse Events or Adverse Events, Reported — 26 Participants
Phase 3 N=111 Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
Leukemia, Acute Lymphoblastic
Primary: Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) — 7.4; NA months — p=< 0.001
Phase 3 N=598 Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase. — 91.6; 90.7 Percentage of…
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Phase 2 N=10 Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia
Primary: Occurrence of a Dose-Limiting Toxicity (Phase 1) — 0; 1; 4; 5 Participants
Phase 3 N=74 Phase III B in Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 69 Participants
Phase 3 N=800 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Drug/Agent Toxicity by Tissue/Organ · Leukemia
Primary: Asparaginase-Related Toxicity Rate — 26; 28 percentage of participants — p=.60
Phase 2 N=116 Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
Recurrent Childhood Acute Lymphoblastic Leukemia
Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants
Phase 2 N=93 Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Phase I: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 1; 2; 1 participants
Phase 3 N=218 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia · Acute Undifferentiated Leukemia · Childhood T Acute Lymphoblastic Leukemia
Primary: Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2) — 35.82 percentage probability
Phase 3 N=9,350 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia · Adult B Lymphoblastic Lymphoma · Ann Arbor Stage I B Lymphoblastic Lymphoma
Primary: Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization — 95.05; 94.17 percent probability
Phase 3 N=63 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia · Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Primary: Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy — 79.8; 83.2; 66.7 Percent probability
Phase 2 N=30 Treatment of Older Adults With Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Overall Survival at One Year — 19 Participants
N/A N=123 Improving Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL Weight in ALL)
B Precursor Type Acute Leukemia
Primary: Fat Mass — 5.1; 10.7 percent change in fat mass
Phase 2 N=57 Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Primary: Disease Free Survival — 1.7 years
Phase 1 N=21 Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
ALL · B Cell Lymphoma · Leukemia
Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…
Phase 2 N=46 A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Primary: Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL) — 0 Percentage of participants
Phase 2 N=106 Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL
Acute Lymphoblastic Leukemia
Primary: Number of Subjects With Event-Free Survival in Patients With Newly Diagnosed VHR B-ALL or High-risk Relapse of B-ALL 1 Year After Treatment. — 68.9 percentage of subjects